Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Nemtabrutinib, a Wild-Type and C481S-Mutated Bruton Tyrosine Kinase Inhibitor for B-Cell Malignancies: Updated Analysis of the Open-Label Phase 1/2 Dose-Expansion Bellwave-001 Study

Jennifer A. Woyach, Ian W. Flinn, Farrukh T. Awan, Herbert Eradat, Danielle Brander, Michael Tees, Sameer A. Parikh, Tycel J. Phillips, Razi Ghori, Nishitha M. Reddy, Mohammed Z.H. Farooqui, John C. Byrd, Deborah M. Stephens

Blood (2022) 140 (Supplement 1): 7004–7006.

https://doi.org/10.1182/blood-2022-163596

Published: 2022

Journal Articles

Preliminary Efficacy and Safety of MK-1026, a Non-Covalent Inhibitor of Wild-Type and C481S Mutated Bruton Tyrosine Kinase, in B-Cell Malignancies: A Phase 2 Dose Expansion Study

Jennifer A. Woyach, Ian W. Flinn, Farrukh T. Awan, Herbert Eradat, Danielle M. Brander, Michael Tees, Sameer A. Parikh, Tycel Phillips, Wayne Wang, Nishitha M. Reddy, Mohammed Z.H. Farooqui, John C. Byrd, Deborah M. Stephens

Blood (2021) 138 (Supplement 1): 392.

https://doi.org/10.1182/blood-2021-148672

Published: 2021

Journal Articles

Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab

Blood (2019) 133 (19): 2031–2042.

https://doi.org/10.1182/blood-2018-08-870238

Published: 2019

Includes: Supplemental data

Journal Articles

Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL

Blood (2017) 129 (19): 2612–2615.

https://doi.org/10.1182/blood-2016-12-737346

Published: 2017

Includes: Supplemental data

Journal Articles

Interim Absolute Lymphocyte Count (ALC) As a Predictor of Survival in Hodgkin Lymphoma

Tarsheen K. Sethi, MD MS, Van T Nguyen, MD, David S Morgan, MD, John P. Greer, MD, Nishitha M Reddy, M.B.B.S.

Blood (2015) 126 (23): 2640.

https://doi.org/10.1182/blood.V126.23.2640.2640

Published: 2015

Journal Articles

MYC/BCL2 Double Hit Lymphoma: What Really Matters

Annapurna Saksena, MD, Parth Desai, MD, Zhuang Zuo, MD PhD, Jie Xu, MD, Pei Lin, MD, Adam C. Seegmiller, MD PhD, C. Cameron Yin, MDPhD, Guilin Tang, MD, Roberto N. Miranda, MD, Jeffrey L. Jorgensen, MD PhD, Nishitha M Reddy, M.B.B.S., L. Jeffrey Medeiros, Shaoying Li, MD

Blood (2015) 126 (23): 3909.

https://doi.org/10.1182/blood.V126.23.3909.3909

Published: 2015

Journal Articles

Differences in Outcome of Patients with Syncytial Variant Hodgkin Lymphoma (HL) Compared with Typical Nodular Sclerosis HL

Tarsheen K. Sethi, MD MS, Van T Nguyen, MD, Shaoying Li, MD, David S Morgan, MD, John P. Greer, MD, Nishitha M Reddy, M.B.B.S.

Blood (2015) 126 (23): 1441.

https://doi.org/10.1182/blood.V126.23.1441.1441

Published: 2015

Journal Articles

Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab Following Standard Chemotherapy for Patients with Intermediate-High/High Risk Diffuse Large B-Cell Lymphoma (DLBCL) - Final Results

Nishitha M Reddy, M.B.B.S., David S Morgan, MD, John P Greer, Heidi Chen, Steven I. Park, MD, Kristy L. Richards, PhD MD

Blood (2015) 126 (23): 2739.

https://doi.org/10.1182/blood.V126.23.2739.2739

Published: 2015

Journal Articles

Hematologic and Immunologic Function and Patient Well-Being for the Phase III RESONATE TM Study of Ibrutinib Vs Ofatumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Blood (2014) 124 (21): 4696.

https://doi.org/10.1182/blood.V124.21.4696.4696

Published: 2014

Journal Articles

Combined Modality Approach for Early Stage Unfavorable Hodgkin Lymphoma- Can We Avoid Radiation Therapy Based on Interim PET Imaging?

Van T Nguyen, MD, Judy P Tsai, MD, John P Greer, MD, David S Morgan, MD, Nishitha M Reddy, M.B.B.S.

Blood (2014) 124 (21): 5430.

https://doi.org/10.1182/blood.V124.21.5430.5430

Published: 2014

Journal Articles

A Phase 2 Trial of Induction Chemotherapy with ABVD Followed By Brentuximab Vedotin Consolidation in Patients with Previously Untreated Non-Bulky Stage I or II Hodgkin Lymphoma

Steven I. Park, MD, Kristy L. Richards, PhD MD, Oludamilola Olajide, MBBS, Nishitha M Reddy, M.B.B.S., Nilanjan Ghosh, MD PhD, Elizabeth E. Budde, MD PhD, Matthew C. Foster, MD, Allison M. Deal, MS, Jeanne F. Noe, PharmD, Thomas C. Shea, MD, Stephen M. Ansell, MD PhD

Blood (2014) 124 (21): 4431.

https://doi.org/10.1182/blood.V124.21.4431.4431

Published: 2014

Journal Articles

Thyroid Dysfunction in Patients with Diffuse Large B-Cell Lymphoma Receiving Lenalidomide May be Mediated By TNF-α

Wade T Iams, MD, Megan L Hames, Judy Peih-Ying P Tsai, MD, Kimberly B Dahlman, PhD, Mahsa Talbott, PharmD, BCOP, Kristy L. Richards, MDPhD, Nishitha M. Reddy, MBBS

Blood (2014) 124 (21): 4438.

https://doi.org/10.1182/blood.V124.21.4438.4438

Published: 2014

Journal Articles

Comprehensive Hybrid Capture-Based Genomic Profiling of T-Cell Leukemias and Lymphomas Reveals Targetable JAK1 and JAK3 Co-Existing Mutations

Utpal P. Dave, MD, Norma Palma, PhD, Kai Wang, MDPhD, Nishitha M Reddy, M.B.B.S., Siraj Ali, MDPhD, Rati Tripathi, PhD, Allison Greenplate, BS, Jonathan Michael Irish, PhD, Derya Unutmaz, MD, Phil J Stephens, PhD, Vincent A. Miller, MD

Blood (2014) 124 (21): 1672.

https://doi.org/10.1182/blood.V124.21.1672.1672

Published: 2014

Journal Articles

Phase II Randomized Study Of Lenalidomide Or Lenalidomide and Rituximab As Maintenance Therapy Following Standard Chemotherapy For Patients With Intermediate-High/High Risk Diffuse Large B-Cell Lymphoma (DLBCL)

Nishitha M. Reddy, MD, David S. Morgan, MD, Steven I. Park, MD, John P Greer, MD, Kristy L. Richards, MD PhD

Blood (2013) 122 (21): 3061.

https://doi.org/10.1182/blood.V122.21.3061.3061

Published: 2013

Journal Articles

Role Of Aggressive Chemotherapeutic Regimens In Double Hit Lymphoma- Can Alternate Aggressive Induction Regimens Overcome The Poor Prognosis Of Diffuse Large B Cell Lymphoma?

Judy Tsai, M.D., John P Greer, MD, David S. Morgan, MD, Shaoying Li, MD, Nishitha M. Reddy, MD

Blood (2013) 122 (21): 4361.

https://doi.org/10.1182/blood.V122.21.4361.4361

Published: 2013

Journal Articles

MYC Gene Single Hit Diffuse Large B Cell Lymphoma Behaves Similarly To MYC/BCL2 Double Hit Lymphoma and Needs Similar Aggressive Treatment

Xuan J. Wang, MD, Nishitha M. Reddy, MD, Shaoying Li, MD

Blood (2013) 122 (21): 4313.

https://doi.org/10.1182/blood.V122.21.4313.4313

Published: 2013

Journal Articles

Comparison of Autologous Vs. Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma

Nishitha M. Reddy, MD, Olalekan O Oluwole, MBBS, MPH, John P Greer, MD, David S Morgan, MD, Stacey Goodman, MD, Brian Engelhardt, MD, Wichai Chinratanalab, MD, Adetola A Kassim, MD, Madan Jagasia, MBBS, MS, Bipin N. Savani, MD

Blood (2012) 120 (21): 2036.

https://doi.org/10.1182/blood.V120.21.2036.2036

Published: 2012

Journal Articles

A Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab As Maintenance Therapy Following R-CHOP Chemotherapy for Patients with High Risk Diffuse Large B-Cell Lymphoma

Nishitha M. Reddy, MD, Rhea M Simons, RN, Meghan E Caldwell, NP, Heidi Chen, PhD, Madan Jagasia, MBBS, MS, David S Morgan, MD, Steven I. Park, MD, John P Greer, MD, Kristy L. Richards, PhD, MD

Blood (2012) 120 (21): 3668.

https://doi.org/10.1182/blood.V120.21.3668.3668

Published: 2012

Journal Articles

Evidence-Based, Patient-Specific Guidelines Provide Efficient and Cost-Effective Molecular and Cytogenetic Testing in Hematologic Malignancy

Adam C. Seegmiller, MD, PhD, Annette S. Kim, MD, PhD, Claudio A. Mosse, MD, PhD, Mia A. Levy, MD, PhD, Mary Ann Thompson, MD, PhD, Megan K. Kressin, MD, Madan H. Jagasia, MD, Stephen A. Strickland, MD, MSCI, Nishitha M. Reddy, MD, Kristy J. Sinkfield, Samuel A. Santoro, MD, PhD, Mary M. Zutter, MD

Blood (2011) 118 (21): 2073.

https://doi.org/10.1182/blood.V118.21.2073.2073

Published: 2011

Journal Articles

Combination Chemotherapy with Rituximab, Gemcitabine, Vinorelbine and Liposomal Doxorubicin As a Salvage Regimen for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Patrick L Stevens, MD, Mahsa Talbott, Meghan E Caldwell, NP, David S Morgan, MD, Annette S. Kim, MD, PhD, John P Greer, MD, Nishitha M. Reddy, MD

Blood (2011) 118 (21): 4954.

https://doi.org/10.1182/blood.V118.21.4954.4954

Published: 2011

NARROW

Efficacy and Safety of Nemtabrutinib, a Wild-Type and C481S-Mutated Bruton Tyrosine Kinase Inhibitor for B-Cell Malignancies: Updated Analysis of the Open-Label Phase 1/2 Dose-Expansion Bellwave-001 Study

Preliminary Efficacy and Safety of MK-1026, a Non-Covalent Inhibitor of Wild-Type and C481S Mutated Bruton Tyrosine Kinase, in B-Cell Malignancies: A Phase 2 Dose Expansion Study

Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab

Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL

Interim Absolute Lymphocyte Count (ALC) As a Predictor of Survival in Hodgkin Lymphoma

MYC/BCL2 Double Hit Lymphoma: What Really Matters

Differences in Outcome of Patients with Syncytial Variant Hodgkin Lymphoma (HL) Compared with Typical Nodular Sclerosis HL

Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab Following Standard Chemotherapy for Patients with Intermediate-High/High Risk Diffuse Large B-Cell Lymphoma (DLBCL) - Final Results

Hematologic and Immunologic Function and Patient Well-Being for the Phase III RESONATE TM Study of Ibrutinib Vs Ofatumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Combined Modality Approach for Early Stage Unfavorable Hodgkin Lymphoma- Can We Avoid Radiation Therapy Based on Interim PET Imaging?

A Phase 2 Trial of Induction Chemotherapy with ABVD Followed By Brentuximab Vedotin Consolidation in Patients with Previously Untreated Non-Bulky Stage I or II Hodgkin Lymphoma

Thyroid Dysfunction in Patients with Diffuse Large B-Cell Lymphoma Receiving Lenalidomide May be Mediated By TNF-α

Comprehensive Hybrid Capture-Based Genomic Profiling of T-Cell Leukemias and Lymphomas Reveals Targetable JAK1 and JAK3 Co-Existing Mutations

Phase II Randomized Study Of Lenalidomide Or Lenalidomide and Rituximab As Maintenance Therapy Following Standard Chemotherapy For Patients With Intermediate-High/High Risk Diffuse Large B-Cell Lymphoma (DLBCL)

Role Of Aggressive Chemotherapeutic Regimens In Double Hit Lymphoma- Can Alternate Aggressive Induction Regimens Overcome The Poor Prognosis Of Diffuse Large B Cell Lymphoma?

MYC Gene Single Hit Diffuse Large B Cell Lymphoma Behaves Similarly To MYC/BCL2 Double Hit Lymphoma and Needs Similar Aggressive Treatment

Comparison of Autologous Vs. Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma

A Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab As Maintenance Therapy Following R-CHOP Chemotherapy for Patients with High Risk Diffuse Large B-Cell Lymphoma

Evidence-Based, Patient-Specific Guidelines Provide Efficient and Cost-Effective Molecular and Cytogenetic Testing in Hematologic Malignancy

Combination Chemotherapy with Rituximab, Gemcitabine, Vinorelbine and Liposomal Doxorubicin As a Salvage Regimen for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only